STX209 meets autism endpoint

Seaside Therapeutics Inc. (Cambridge, Mass.) said STX209 met the primary endpoint of significantly improving irritability subscale scores on the ABC-I from baseline to week 8 in the per protocol population in a Phase II trial to treat autism spectrum disorders (ASD). Seaside said it plans to start "late-stage" clinical trials of the GABA B receptor agonist in both fragile X syndrome and autism this year after meeting with FDA. The per protocol population included 25 patients. ...